Results 191 to 200 of about 169,027 (313)

Satralizumab after inebilizumab treatment in a patient with recurrent neuromyelitis optica spectrum disorder: A case report. [PDF]

Medicine (Baltimore)
Li D, Ye J, Hong Z, Xiao H.
europepmc   +1 more source

CT‐P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study

Allergy, EarlyView.
This study investigated the therapeutic equivalence of CT‐P39 (an omalizumab biosimilar) and EU‐approved reference omalizumab (ref‐OMA) in patients with chronic spontaneous urticaria. Therapeutic equivalence between CT‐P39 and ref‑OMA (300 mg) was demonstrated by the primary endpoint – confidence intervals of the treatment difference in mean change ...
Sarbjit S. Saini, Marcus Maurer, Yevgeniya Dytyatkovska, Ewa Springer, Maria Ratkova, Borislava Krusheva, Chun Wook Park, Grazyna Pulka, Marta Chełmińska, Adam Reich, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Jieun Ka, Jongho Kim, Clive Grattan   +16 more
wiley   +1 more source

Advancements in cell-penetrating monoclonal antibody treatment. [PDF]

Oncotarget
Pradeep SP, Bahal R.
europepmc   +1 more source

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX‐622

Allergy, EarlyView.
SCF and TSLP expression are known to drive unique immune responses leading to the onset of allergic and inflammatory diseases. Here, we describe the characterization of a novel bsAb, CDX‐622, that targets SCF and TSLP. CDX‐622 inhibits MC functions through SCF starvation and Type 2 inflammatory responses via TSLP inhibition.
Michael B. Murphy, Laura Vitale, Thomas O'Neill, Deena M. Maurer, Linda Malenchek, Andrea Crocker, Colleen Patterson, Laura Mills‐Chen, Virginia Saley, Nicole M. Antczak, James M. Boyer, Kelly M. McManus, Noe Rico Montanari, Russell A. Hammond, Joel Goldstein, Lawrence J. Thomas, Tibor Keler, Diego Alvarado   +17 more
wiley   +1 more source

Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications. [PDF]

Antib Ther
Blythe EN, Barreira C, Fink C, Brown A, Weaver LC, Dekaban GA.   +5 more
europepmc   +1 more source

Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps

Allergy, EarlyView.
ABSTRACT Emerging biologics that selectively target key cytokines present a promising therapeutic alternative for patients suffering from severe, uncontrollable chronic rhinosinusitis with nasal polyps (CRSwNP). Despite the limited availability of registered biologics for CRSwNP treatment in China, the country is experiencing rapid development in this ...
Mu Xian, Bing Yan, Xicheng Song, Jianjun Chen, Jun Tang, Yan Jiang, Lijia Wan, Wen Liu, Jinmei Xue, Zhiwei Cao, Yafeng Yu, Xiangli Yang, Li Shi, Guangke Wang, Yu Xu, Yucheng Yang, Jing Ye, Luyun Jiang, Fang Quan, Guolin Tan, Feng Liu, Zhendong Xu, Xiaowen Zhang, Jiping Li, Lizhong Su, Yi Yang, Jiangang Fan, Gang He, Li Zhu, Xiangdong Wang, Ming Wang, Shen Shen, Jian Li, Huabin Li, Xin Wei, Hongmeng Yu, Zheng Liu, Ruixia Ma, Huanhai Liu, Jianfeng Liu, Wei Lv, Qintai Yang, Dongdong Zhu, Lei Cheng, Chengshuo Wang, Luo Zhang   +45 more
wiley   +1 more source

A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response. [PDF]

Sci Transl Med
Gu Y, Singh S, Alqarihi A, Alkhazraji S, Gebremariam T, Youssef EG, Liu H, Fan X, Jiang WR, Andes D, Cochrane TR, Schwartz JA, Filler SG, Uppuluri P, Ibrahim AS.   +14 more
europepmc   +1 more source

Neutralization of Marinobufagenin Demonstrates Efficacy In Vitro and In Vivo in Models of Pre-Eclampsia. [PDF]

Biomedicines
Pantho AF, Zaman M, Afroze SH, Wages JM, Yu B, Larrick JW, Kuehl TJ, Vora N, Uddin MN.   +8 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study

Alimentary Pharmacology &Therapeutics, EarlyView.
This real‐world multicenter study assessed the short‐term effectiveness and safety of mirikizumab induction therapy in ulcerative colitis patients. Among 52 patients, the median partial Mayo score significantly decreased from week 0 to 12, and 44.2% achieved clinical remission, with no treatment‐related discontinuations or deaths.
Yasuhiro Takagi, Toshiyuki Sato, Takanori Nishiguchi, Akira Nogami, Masataka Igeta, Soichi Yagi, Maiko Ikenouchi, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Toshihiko Tomita, Hirokazu Fukui, Masayuki Fukata, Taku Kobayashi, Shinichiro Shinzaki   +14 more
wiley   +1 more source

Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody. [PDF]

Pharmaceuticals (Basel)
Yao Y, Yang X, Li J, Guo E, Wang H, Sun C, Hong Z, Zhang X, Jia J, Wang R, Ma J, Dai Y, Deng M, Yu C, Sun L, Xie L.   +15 more
europepmc   +1 more source